Advertisement

American Journal of Cardiovascular Drugs

, Volume 10, Issue 1, pp 11–28 | Cite as

Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia

  • Michael S. Kostapanos
  • Haralampos J. Milionis
  • Moses S. Elisaf
Review Article

Abstract

HMG-CoA reductase inhibitors (statins) are the mainstay in the pharmacologic management of dyslipidemia. Since they are widely prescribed, their safety remains an issue of concern. Rosuvastatin has been proven to be efficacious in improving serum lipid profiles. Recently published data from the JUPITER study confirmed the efficacy of this statin in primary prevention for older patients with multiple risk factors and evidence of inflammation.

Rosuvastatin exhibits high hydrophilicity and hepatoselectivity, as well as low systemic bioavailability, while undergoing minimal metabolism via the cytochrome P450 system. Therefore, rosuvastatin has an interesting pharmacokinetic profile that is different from that of other statins. However, it remains to be established whether this may translate into a better safety profile and fewer drug-drug interactions for this statin compared with others. Herein, we review evidence with regard to the safety of this statin as well as its interactions with agents commonly prescribed in the clinical setting.

As with other statins, rosuvastatin treatment is associated with relatively low rates of severe myopathy, rhabdomyolysis, and renal failure. Asymptomatic liver enzyme elevations occur with rosuvastatin at a similarly low incidence as with other statins. Rosuvastatin treatment has also been associated with adverse effects related to the gastrointestinal tract and central nervous system, which are also commonly observed with many other drugs. Proteinuria induced by rosuvastatin is likely to be associated with a statin-provoked inhibition of low-molecular-weight protein reabsorption by the renal tubules. Higher doses of rosuvastatin have been associated with cases of renal failure. Also, the co-administration of rosuvastatin with drugs that increase rosuvastatin blood levels may be deleterious for the kidney. Furthermore, rhabdomyolysis, considered a class effect of statins, is known to involve renal damage. Concerns have been raised by findings from the JUPITER study suggesting that rosuvastatin may slightly increase the incidence of physician-reported diabetes mellitus, as well as the levels of glycated hemoglobin in older patients with multiple risk factors and low-grade inflammation. Clinical trials proposed no increase in the incidence of neoplasias with rosuvastatin treatment compared with placebo.

Drugs that antagonize organic anion transporter protein 1B1-mediated hepatic uptake of rosuvastatin are more likely to interact with this statin. Clinicians should be cautious when rosuvastatin is co-administered with vitamin K antagonists, cyclosporine (ciclosporin), gemfibrozil, and antiretroviral agents since a potential pharmacokinetic interaction with those drugs may increase the risk of toxicity. On the other hand, rosuvastatin combination treatment with fenofibrate, ezetimibe, omega-3-fatty acids, antifungal azoles, rifampin (rifampicin), or clopidogrel seems to be safe, as there is no evidence to support any pharmacokinetic or pharmacodynamic interaction of rosuvastatin with any of these drugs.

Rosuvastatin therefore appears to be relatively safe and well tolerated, sharing the adverse effects that are considered class effects of statins. Practitioners of all medical practices should be alert when rosuvastatin is prescribed concomitantly with agents that may increase the risk of rosuvastatin-associated toxicity.

Keywords

Statin Clopidogrel Fenofibrate Rosuvastatin Ezetimibe 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This review was prepared independently; no company or institution supported it financially. Drs Milionis and Elisaf have given talks, attended conferences, and participated in trials sponsored by AstraZeneca. Dr Kostapanos has no conflicts of interest that are directly relevant to the content of this review. Industry had no role in the design, conduct, analysis, or publication of this review.

References

  1. 1.
    Ong HT. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. Q J Med 2005; 98: 599–614.CrossRefGoogle Scholar
  2. 2.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.Google Scholar
  3. 3.
    Sever PS, Dahlöf B, Poulter NR, et al., on behalf of the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.PubMedCrossRefGoogle Scholar
  4. 4.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.PubMedCrossRefGoogle Scholar
  5. 5.
    Baigent C, Keech A, Kearney PM, et al., Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78.PubMedCrossRefGoogle Scholar
  6. 6.
    Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al., on behalf of the American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024–8.PubMedCrossRefGoogle Scholar
  8. 8.
    LaRosa JC, Grundy SM, Waters DD, et al., on behalf of Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35.PubMedCrossRefGoogle Scholar
  9. 9.
    Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438–45.PubMedCrossRefGoogle Scholar
  10. 10.
    Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97S: 27–31C.CrossRefGoogle Scholar
  11. 11.
    Grundy SM. The issue of statin safety: where do we stand? Circulation 2005; 111: 3016–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 2003; 92: 152–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Schuster H, Barter PJ, Stender S, et al., on behalf of the Effective Reductions in Cholesterol Using Rosuvastatin Therapy I Study Group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Milionis HJ, Rizos E, Kostapanos M, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006; 22: 1123–31.PubMedCrossRefGoogle Scholar
  15. 15.
    Davidson MH, Clark JA, Glass LM, et al. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006; 97(8A): 32–43C.CrossRefGoogle Scholar
  16. 16.
    McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003; 4: 9–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71–105.PubMedCrossRefGoogle Scholar
  18. 18.
    Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004; 94: 882–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update on 16 876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107: 433–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Brown WV, Bays HE, Hassman DR, et al., on behalf of the Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002; 44: 1036–43.CrossRefGoogle Scholar
  21. 21.
    Leiter LA, Rosenson RS, Stein E, et al., on behalf of the POLARIS Study investigators. Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194: e154–64.PubMedCrossRefGoogle Scholar
  22. 22.
    Ferdinand KC, Clark LT, Watson KE, et al., on behalf of the ARIES Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 2006; 97: 229–35.PubMedCrossRefGoogle Scholar
  23. 23.
    Tavazzi L, Maggioni AP, Marchioli R, et al., on behalf of the GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Ballantyne CM, Weiss R, Moccetti T, et al., on behalf of the EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007; 99: 673–80.PubMedCrossRefGoogle Scholar
  25. 25.
    Stalenhoef AF, Ballantyne CM, Sarti C, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005; 26: 2664–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Strandberg TE, Feely J, Sigurdsson E. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther 2004; 26: 1821–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Wolffenbuttel BH, Franken AA, Vincent HH. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes: CORALL study. J Intern Med 2005; 257: 531–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Lloret R, Ycas J, Stein M, et al. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol 2006; 98: 768–73.PubMedCrossRefGoogle Scholar
  29. 29.
    Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 2006; 151: 975.e1–9.CrossRefGoogle Scholar
  30. 30.
    Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Deedwania PC, Gupta M, Stein M, et al. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS trial). Am J Cardiol 2007; 99: 1538–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Insull Jr W, Ghali JK, Hassman DR, et al. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc 2007; 82: 543–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Crouse 3rd JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with sub-clinical atherosclerosis: the METEOR trial. JAMA 2007; 297: 1344–53.PubMedCrossRefGoogle Scholar
  34. 34.
    Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009; 204: 208–15.PubMedCrossRefGoogle Scholar
  35. 35.
    Ballantyne CM, Miller E, Chitra R. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther 2004; 26: 1855–64.PubMedCrossRefGoogle Scholar
  36. 36.
    Glueck CJ, Aregawi D, Agloria M, et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther 2006; 28: 933–42.PubMedCrossRefGoogle Scholar
  37. 37.
    Krum H, Ashton E, Reid C, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007; 13: 1–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Saito Y, Yamada N, Shirai K, et al. Effect of rosuvastatin 5–20mg on triglycerides and other lipid parameters in Japanese patients with hypertriglycer-idemia. Atherosclerosis 2007; 194: 505–11.PubMedCrossRefGoogle Scholar
  39. 39.
    Saito Y, Goto Y, Dane A, et al. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2003; 10: 329–36.PubMedCrossRefGoogle Scholar
  40. 40.
    Schwartz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J 2004; 148: H1–8.CrossRefGoogle Scholar
  41. 41.
    Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004; 64: 137–51.PubMedCrossRefGoogle Scholar
  42. 42.
    McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007; 192: 432–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Capuzzi DM, Morgan JM, Weiss RJ, et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003; 91: 1304–10.PubMedCrossRefGoogle Scholar
  44. 44.
    Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia: Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 2006; 7: 35.PubMedCrossRefGoogle Scholar
  45. 45.
    Kurabayashi M, Yamazaki T. Superior benefit of aggressive lipid-lowering therapy for high-risk patients using statins: the SUBARU study — more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. J Atheroscler Thromb 2008; 15:314–23.PubMedCrossRefGoogle Scholar
  46. 46.
    Stein EA, Amerena J, Ballantyne CM, et al. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol 2007; 100: 1387–96.PubMedCrossRefGoogle Scholar
  47. 47.
    Sorokin AV, Duncan B, Panetta R, et al. Rhabdomyolysis associated with pomegranate juice consumption. Am J Cardiol 2006; 98: 705–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Famularo G, Miele L, Minisola G, et al. Liver toxicity of rosuvastatin therapy. World J Gastroenterol 2007; 13: 1286–8.PubMedGoogle Scholar
  49. 49.
    Antonopoulos S, Mikros S, Mylonopoulou M, et al. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006; 184: 233–4.PubMedCrossRefGoogle Scholar
  50. 50.
    Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102: 52–60.PubMedCrossRefGoogle Scholar
  51. 51.
    Vidt DG, Harris S, McTaggart F, et al. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006; 97: 1602–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Fellstrom B, Holdaas H, Jardine AG, et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res 2007; 30: 314–22.PubMedCrossRefGoogle Scholar
  53. 53.
    Tiwari A. An overview of statin-associated proteinuria. Drug Discov Today 2006; 11: 458–64.PubMedCrossRefGoogle Scholar
  54. 54.
    Kostapanos MS, Milionis HJ, Filippatos TD, et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 2007; 29: 1403–14.PubMedCrossRefGoogle Scholar
  55. 55.
    Kostapanos MS, Milionis HJ, Saougos VG, et al. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. J Cardiovasc Pharmacol Ther 2007; 12: 292–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Kostapanos MS, Milionis HJ, Gazi I, et al. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacol 2006; 46: 1337–43.PubMedCrossRefGoogle Scholar
  57. 57.
    Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556–65.PubMedCrossRefGoogle Scholar
  58. 58.
    Singh S, Nautiyal A, Dolan JG. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin: is statin induced pancreatitis a class effect? JOP 2004; 5: 502–4.PubMedGoogle Scholar
  59. 59.
    Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007; 195: 7–16.PubMedCrossRefGoogle Scholar
  60. 60.
    Galatti L, Polimeni G, Salvo F, et al. Short-term memory loss associated with rosuvastatin. Pharmacotherapy 2006; 26: 1190–2.PubMedCrossRefGoogle Scholar
  61. 61.
    Tapia-Perez JH, Sanchez-Aguilar M, Torres-Corzo JG, et al. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma 2008; 25: 1011–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Oteri A, Catania MA, Travaglini R, et al. Gynecomastia possibly induced by rosuvastatin. Pharmacotherapy 2008; 28: 549–51.PubMedCrossRefGoogle Scholar
  63. 63.
    Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 2005; 17: 589–90.PubMedCrossRefGoogle Scholar
  64. 64.
    Finsterer J, Stollberger C. Myalgia, hyper-CK-aemia, and hypocoagulability in a patient under rosuvastatin and warfarin [letter]. Eur J Neurol 2005; 12: 660.PubMedCrossRefGoogle Scholar
  65. 65.
    Mondillo S, Ballo P, Galderisi M. Rosuvastatin-acenocoumarol interaction. Clin Ther 2005; 27: 782–4.PubMedCrossRefGoogle Scholar
  66. 66.
    Simonson SG, Martin PD, Mitchell PD, et al. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005; 45: 927–34.PubMedCrossRefGoogle Scholar
  67. 67.
    Jindal D, Tandon M, Sharma S, et al. Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects. Eur J Clin Pharmacol 2005; 61: 621–5.PubMedCrossRefGoogle Scholar
  68. 68.
    Launay-Vacher V, Izzedine H, Deray G. Statins’ dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol 2005; 101: 9–17.PubMedCrossRefGoogle Scholar
  69. 69.
    Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004; 76: 167–77.PubMedCrossRefGoogle Scholar
  70. 70.
    Brinton EA. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio? Curr Atheroscler Rep 2008; 10: 25–32.PubMedCrossRefGoogle Scholar
  71. 71.
    Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1280–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Martin PD, Dane AL, Schneck DW, et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003; 25: 459–71.PubMedCrossRefGoogle Scholar
  73. 73.
    Ireland JH, Eggert CH, Arendt CJ, et al. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med 2005; 142: 949–50.PubMedGoogle Scholar
  74. 74.
    Dedhia V, Munsi SC. Myopathy caused by a combination rosuvastatin and fenofibrate. J Assoc Physicians India 2007; 55: 152–3.PubMedGoogle Scholar
  75. 75.
    Zhu T, Awni WM, Hosmane B, et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol 2009; 49: 63–71.PubMedGoogle Scholar
  76. 76.
    Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004; 75: 455–63.PubMedCrossRefGoogle Scholar
  77. 77.
    Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004; 20: 1185–95.PubMedCrossRefGoogle Scholar
  78. 78.
    Capuzzi DM, Morgan JM, Carey CM, et al. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. Prev Cardiol 2004; 7: 176–81.PubMedCrossRefGoogle Scholar
  79. 79.
    Gosai P, Liu J, Doyle RT, et al. Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. Expert Opin Pharmacother 2008; 9: 2947–53.PubMedCrossRefGoogle Scholar
  80. 80.
    Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003; 73: 322–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003; 55: 94–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002; 58: 527–31.PubMedCrossRefGoogle Scholar
  83. 83.
    Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003; 59: 51–6.PubMedGoogle Scholar
  84. 84.
    Zhang W, Deng S, Chen XP, et al. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther 2008; 30: 1283–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Calza L, Colangeli V, Manfredi R, et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005; 19: 1103–5.PubMedCrossRefGoogle Scholar
  86. 86.
    Calza L, Manfredi R, Colangeli V, et al. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008; 6: 572–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008; 47: 570–8.PubMedCrossRefGoogle Scholar
  88. 88.
    van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007; 12: 1127–32.PubMedGoogle Scholar
  89. 89.
    Busti AJ, Bain AM, Hall 2nd RG, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2008; 51: 605–10.PubMedCrossRefGoogle Scholar
  90. 90.
    Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 2005; 35: 476–81.PubMedCrossRefGoogle Scholar
  91. 91.
    Riondino S, Petrini N, Donato L, et al. Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. J Thromb Thrombolysis 2009; 28: 151–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Martin PD, Kemp J, Dane AL, et al. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 2002; 42: 1352–7.PubMedCrossRefGoogle Scholar
  93. 93.
    Merz T, Fuller SH. Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone. Am J Health Syst Pharm 2007; 64: 1818–21.PubMedCrossRefGoogle Scholar
  94. 94.
    He YJ, Zhang W, Tu JH, et al. Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin. Drug Metab Dispos 2008; 36: 1453–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Deng JW, Shon JH, Shin HJ, et al. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res 2008; 25: 1807–14.PubMedCrossRefGoogle Scholar
  96. 96.
    Martin PD, Schneck DW, Dane AL, et al. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Curr Med Res Opin 2008; 24: 1231–5.PubMedCrossRefGoogle Scholar
  97. 97.
    Simonson SG, Martin PD, Warwick MJ, et al. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol 2004; 57: 279–86.PubMedCrossRefGoogle Scholar
  98. 98.
    Fan L, Zhang W, Guo D, et al. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin Pharmacol Ther 2008; 83: 471–6.PubMedCrossRefGoogle Scholar
  99. 99.
    Hidaka M, Okumura M, Fujita K, et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005; 33: 644–8.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Michael S. Kostapanos
    • 1
  • Haralampos J. Milionis
    • 1
  • Moses S. Elisaf
    • 1
  1. 1.Department of Internal Medicine, School of MedicineUniversity of IoanninaIoanninaGreece

Personalised recommendations